Company / Operating Cash Flow
Ligand Pharmaceuticals, Inc. Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
$49.4M
FY2025
5-year range
$49.4M / $137.8M
FY2021-FY2025
Trend
-49.1%
vs FY2024
Sector context
#61 of 216
Health Care
What the data says
At $49M, Ligand Pharmaceuticals, Inc.'s operating cash flow ranks #61 of 216 in the Health Care sector. Operating Cash Flow has fluctuated over the past 10 years, ranging from -$29M in FY2019 to $194M in FY2018.
Based on SEC 10-K filings.
$49M in FY2025 with a 5-year CAGR of -2.0%.
Remained stable around $49M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -29.0%
- 5-Year CAGR
- -2.0%
- 10-Year CAGR
- -
Sector benchmark
#61 of 216 in Health CareTop 28% of 216This company $49.4M Sector average $658.7M
▼
-92.5% below sector average
Key checks
Key Insights
- 5-year CAGR of -2.0%, indicating a declining trend.
- In FY2025, operating cash flow decreased 49.1% year-over-year.
- Ranks #61 out of 216 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2018.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $49.4M | -49.1% |
| FY2024 | $97.0M | +95.8% |
| FY2023 | $49.6M | -64.0% |
| FY2022 | $137.8M | +74.9% |
| FY2021 | $78.8M | +44.4% |
| FY2020 | $54.6M | +286.1% |
| FY2019 | -$29.3M | -115.1% |
| FY2018 | $194.1M | +119.1% |
| FY2017 | $88.6M | +45.8% |
| FY2016 | $60.7M | +45.5% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026